Awaiting development: Guidance and quality standards

Showing 61 to 70 of 87

Guidance and quality standards awaiting development
Title	Type
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]	Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]	Technology appraisal guidance
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]	Technology appraisal guidance
Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709]	Technology appraisal guidance
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]	Technology appraisal guidance
Safeguarding adults in care homes	Quality standard
Selinexor with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 to 4 treatment lines in people who have not had pomalidomide [ID6705]	Technology appraisal guidance
Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [ID6717]	Technology appraisal guidance
Semaglutide for managing overweight and obesity in children 6 to 11 years [TSID12381]	Technology appraisal guidance
Sepiapterin for treating hyperphenylalaninaemia in phenylketonuria in people of any age [ID6750]	Technology appraisal guidance